Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Eagle Health Investments LP

Q4 2023 · 13F-HR

Eagle Health Investments LPholdings as filed

Filed 2024-02-12 · accession 0001172661-24-000664

$492.1M
Reported value
22
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
G4705A100ICLRICON PLC$46.7M9.50%165,100CommonSOLE
452327109ILMNILLUMINA INC$44.4M9.02%318,754CommonSOLE
632307104NTRANATERA INC$43.3M8.79%690,862CommonSOLE
46266C105IQVIQVIA HLDGS INC$40.2M8.16%173,595CommonSOLE
252131107DXCMDEXCOM INC$38.4M7.80%309,318CommonSOLE
91307C102UTHRUNITED THERAPEUTICS CORP DEL$37.6M7.63%170,838CommonSOLE
235851102DHRDANAHER CORPORATION$36.5M7.42%157,785CommonSOLE
04016X101ARGXARGENX SE$32.2M6.54%84,590CommonSOLE
02043Q107ALNYALNYLAM PHARMACEUTICALS INC$26.2M5.32%136,756CommonSOLE
89377M109TMDXTRANSMEDICS GROUP INC$24.9M5.05%314,855CommonSOLE
457730109INSPINSPIRE MED SYS INC$23.1M4.69%113,503CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$18.3M3.71%189,356CommonSOLE
69404D108PACBPACIFIC BIOSCIENCES CALIF IN$14.9M3.04%1,522,721CommonSOLE
46120E602ISRGINTUITIVE SURGICAL INC$14.6M2.97%43,390CommonSOLE
74276L105PRCTPROCEPT BIOROBOTICS CORP$14.1M2.87%337,218CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$8.9M1.80%437,911CommonSOLE
00847X104AGIOAGIOS PHARMACEUTICALS INC$7.4M1.50%330,830CommonSOLE
00650F109ADPTADAPTIVE BIOTECHNOLOGIES COR$6.0M1.21%1,214,860CommonSOLE
36118A100FUSION PHARMACEUTICALS INC$5.6M1.13%579,769CommonSOLE
40131M109GHGUARDANT HEALTH INC$3.2M0.66%120,109CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$3.2M0.64%46,300CommonSOLE
516544103LNTHLANTHEUS HLDGS INC$2.7M0.54%43,200CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.